亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.

医学 催眠药 内科学 临床研究阶段 肿瘤科 临床终点 安慰剂 胃肠病学 耐受性 胃食管交界处 临床试验 随机对照试验 腺癌 不利影响 紫杉醇
作者
Rui-Hua Xu,Yanqiao Zhang,Hongming Pan,Jifeng Feng,Tao Zhang,Tianshu Liu,Yanru Qin,Shukui Qin,Xianli Yin,Baorui Liu,Yi Ba,Nong Yang,Pei Jye Voon,Suebpong Tanasanvimon,Chan Zhou,Wan Li Zhang,Lin Shen
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:6 (12): 1015-1024 被引量:1
标识
DOI:10.1016/s2468-1253(21)00313-7
摘要

Summary Background In the global phase 3 RAINBOW study, ramucirumab plus paclitaxel significantly improved overall survival compared with placebo plus paclitaxel in patients with advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. RAINBOW-Asia, a bridging study with similar design to RAINBOW, aimed to evaluate the efficacy and safety of ramucirumab plus paclitaxel for advanced gastric or GEJ adenocarcinoma in Asian, predominantly Chinese, patients. Methods RAINBOW-Asia was a randomised, double-blind, placebo-controlled, phase 3 trial done at 32 centres in China, Malaysia, the Philippines, and Thailand. Adult patients (≥18 years) with metastatic or locally advanced, unresectable gastric or GEJ adenocarcinoma who previously received fluoropyrimidine–platinum-based chemotherapy were randomly assigned with a centralised interactive web response system in a 2:1 ratio to receive ramucirumab 8 mg/kg or placebo intravenously on days 1 and 15 plus paclitaxel 80 mg/m2 intravenously on days 1, 8, and 15 of every 28-day cycle. Randomisation was stratified by Eastern Cooperative Oncology Group performance status and presence of peritoneal metastases. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done in the intention-to-treat population, and safety analysis included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov , NCT02898077 , and has been completed. Findings Between March 2, 2017, and June 30, 2020, 440 patients were randomly assigned to receive ramucirumab plus paclitaxel (n=294) or placebo plus paclitaxel (n=146). Median progression-free survival was 4·14 months (95% CI 3·71–4·30) in the ramucirumab plus paclitaxel group compared with 3·15 months (2·83–4·14) in the placebo plus paclitaxel group (hazard ratio [HR] 0·765, 95% CI 0·613–0·955, p=0·0184). Median overall survival was 8·71 months (95% CI 7·98–9·49) in the ramucirumab plus paclitaxel group and 7·92 months (6·31–9·10) in the placebo plus paclitaxel group (HR 0·963, 95% CI 0·771–1·203, p=0·7426). The most common grade 3 or worse treatment-emergent adverse events were decreased neutrophil count (159 [54%] of 293 patients in the ramucirumab plus paclitaxel group vs 56 [39%] of 145 in the placebo plus paclitaxel group), decreased white blood cell count (127 [43%] vs 42 [29%]), anaemia (46 [16%] vs 24 [17%]), hypertension (21 [7%] vs nine [6%]), and febrile neutropenia (18 [6%] vs one [ Interpretation These findings, along with the results from RAINBOW, support the use of ramucirumab plus paclitaxel as second-line therapy in a predominantly Chinese population with advanced gastric or GEJ adenocarcinoma. Funding Eli Lilly and Company, USA. Translation For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李健应助酷酷豌豆射手采纳,获得10
4秒前
葛觅荷发布了新的文献求助10
7秒前
葛觅荷完成签到,获得积分10
14秒前
suity完成签到,获得积分10
16秒前
酷酷豌豆射手完成签到,获得积分10
20秒前
20秒前
SciGPT应助王十三采纳,获得10
24秒前
45秒前
you发布了新的文献求助10
50秒前
香妃发布了新的文献求助10
52秒前
you完成签到,获得积分10
56秒前
56秒前
丘比特应助you采纳,获得10
1分钟前
1分钟前
JamesPei应助科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
王十三发布了新的文献求助10
1分钟前
1分钟前
科研人完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
花半里里发布了新的文献求助10
1分钟前
wanci应助花半里里采纳,获得10
1分钟前
小不点、大迷糊完成签到,获得积分10
1分钟前
ZhangDaying完成签到 ,获得积分10
2分钟前
2分钟前
小北发布了新的文献求助10
2分钟前
Akim应助开心小阮采纳,获得10
2分钟前
快哒哒哒完成签到,获得积分10
2分钟前
struggling2026完成签到 ,获得积分10
2分钟前
吕懿发布了新的文献求助10
2分钟前
yaoyaoyao完成签到 ,获得积分10
2分钟前
英俊的铭应助吕懿采纳,获得10
2分钟前
2分钟前
pengrui0911完成签到 ,获得积分10
2分钟前
开心小阮发布了新的文献求助10
2分钟前
哈喽发布了新的文献求助20
2分钟前
飞艇完成签到 ,获得积分10
3分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545351
求助须知:如何正确求助?哪些是违规求助? 2175631
关于积分的说明 5600124
捐赠科研通 1896314
什么是DOI,文献DOI怎么找? 946215
版权声明 565334
科研通“疑难数据库(出版商)”最低求助积分说明 503541